AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01808170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cyst deroofing
Description: will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
Study NCT03345082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal injection
Study NCT03345082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection
Study NCT03345082 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: Intravitreal injection
Study NCT03345082 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham intravitreal injection
Description: Sham (mock) intravitreal injection
Study NCT02475993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART app
Description: Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
Study NCT04872946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea
Description: Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
Study NCT04872946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum
Description: Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
Study NCT04872946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
Study NCT03062436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping the standard drug therpy
Description: Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
Study NCT03881254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Autologous Homologous Skin Construct
Description: Application of a autologous human derived skin polar units
Study NCT03062436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative bcrabl recording every month for first 6 months
Description: Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
Study NCT04537156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine
Description: Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT04537156 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent HPV vaccine
Description: Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study NCT03439072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Study NCT03439072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lilly Glucagon
Description: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
Study NCT01417988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Empiric TB treatment
Description: Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
Study NCT01417988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART only arm
Description: ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
Study NCT04124419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Evolve System
Description: EMS and RF Treatment
Study NCT02125422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly tDCS
Description: Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
Study NCT00959049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL's Influenza Virus Vaccine (Afluria)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
Study NCT00959049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine (Fluzone)
Description: 0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
Study NCT03982810 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
Study NCT03497702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60mg/m2 IV every 3 weeks for 4 cycles
Study NCT03497702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 IV every 3 weeks for 4 cycles
Study NCT03497702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 IV every 3 weeks for 4 cycles
Study NCT03881254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing
Study NCT03881254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing
Study NCT03497702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg once daily preoperably
Study NCT03497702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: 3.75 mg SC every 4 weeks for premenopausal patients
Study NCT01752179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesio Tape : Width 5cm ,Length 35cm Y shape
Description: In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application.
Study NCT03917901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Training
Description: Computerized Single-Session Anxiety Sensitivity Reduction Program
Study NCT03917901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Control
Description: Computerized Single-Session Health Information Control
Study NCT03992872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chikungunya
Description: Virus Like Particle
Study NCT03992872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chikungunya
Description: Virus Like Particle
Study NCT02556047 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Star Intradermal Safety Device
Description: Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
Study NCT02510924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Description: tracheal intubation with Airtraq sp vs Airtraq mobile
Study NCT02510924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: tracheal intubation with Airtraq sp vs Airtraq mobile
Study NCT03276793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral testing
Description: Patients will complete a series of cognitive tasks
Study NCT02326675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice
Description: This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
Study NCT02326675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Solution
Description: This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
Study NCT03295500 — intervention group
Intervention type: RADIATION
Intervention: Dose fraction forms
Description: The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
Study NCT01104155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eribulin mesylate + erlotinib
Description: 21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
Study NCT01104155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eribulin mesylate + erlotinib
Description: 28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
Study NCT02378727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active: Comparator Loss Of Resistance Syringe
Description: Lumbar epidural procedure utilizing Loss of Resistance Syringe
Study NCT02378727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: CompuFlo® Epidural System
Description: CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
Study NCT04326075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
Study NCT03853343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Seaweed extract
Description: 1 capsule 3 times per day
Study NCT03853343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule 3 times per day
Study NCT00452478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: 2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
Study NCT03881254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT03881254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT03881254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Collagen Alginate Dressing
Study NCT01743729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast Ophthalmic Solution 5.0%
Study NCT01743729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Lifitegrast Ophthalmic Solution 5.0%
Study NCT03742219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: 1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters.
Study NCT03850665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach (DAA)
Description: Direct Anterior Approach surgery to replace the hip.
Study NCT03850665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Description: Anterolateral approach surgery to replace the hip.
Study NCT01527318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrate treatment
Description: Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
Study NCT01147172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elevess
Description: Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
Study NCT04048122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MultiContext for PD Strategy Training
Description: This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
Study NCT04048122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
Study NCT03576365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICE Intervention Arm
Description: Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms
Study NCT03576365 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Information-Only Arm
Description: General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)
Study NCT03182062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
Study NCT03182062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP Titration Trial
Description: The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
Study NCT01086930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
Study NCT01086930 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
Study NCT03038568 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
Study NCT03182062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung protective ventilation
Description: Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
Study NCT01724411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch type 3
Description: Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
Study NCT03318393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Continuous infusion
Study NCT03318393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Continuous infusion